CTOs on the Move

Current Medical Directions

www.cmdny.com

 
Current Medical Directions is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.cmdny.com
  • 230 Park Ave S
    New York, NY USA 10003
  • Phone: 212.614.4100

Executives

Name Title Contact Details

Similar Companies

American Well

American Well transforms healthcare delivery through telehealth. We make online doctor visits accessible to everyone for one-off care issues like colds or infections, and chronic condition management, such as diabetes or depression. We deliver healthcare into people`s homes and workplaces through our work with top health plans, health systems and employers, as well as our telehealth app, Amwell. A patient using Amwell can connect to a board-certified doctor of their choosing in just minutes for a visit carried out over smartphone, tablet, kiosk, phone, or desktop.

Lexicomm International

Lexicomm International, Ltd. is a Jenkintown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

A.R.E.B.A. Casriel

A.R.E.B.A. Casriel is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lakes Region General Healthcare

LRGHealthcare is committed to providing women in our community with the health services they need. This web page is dedicated to two major areas of women's health: Breast Health and Reproductive Health.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.